Orofer FCM 1K Injection contains Ferric Carboxymaltose (50 mg/ml), an intravenous iron preparation indicated for the treatment of iron deficiency anemia when oral iron preparations are ineffective or cannot be used. This formulation provides a stable complex of iron and carboxymaltose, allowing controlled release of bioavailable iron to replenish iron stores rapidly and effectively. Orofer FCM 1K Injection is particularly beneficial in patients with chronic kidney disease, inflammatory bowel disease, postpartum anemia, or those undergoing chemotherapy, where iron deficiency anemia is prevalent and oral therapy is insufficient or contraindicated. The injection is administered intravenously, enabling direct delivery of iron into the bloodstream, bypassing gastrointestinal absorption issues. Dosage and administration should be individualized based on the patient’s hemoglobin levels, body weight, and iron deficit, with careful monitoring to avoid iron overload. Common adverse effects include transient hypophosphatemia, injection site reactions, and mild gastrointestinal disturbances. Contraindications include known hypersensitivity to ferric carboxymaltose or any component of the formulation, and patients with iron overload conditions such as hemochromatosis. Orofer FCM 1K Injection is a valuable therapeutic option for rapid correction of iron deficiency anemia, improving patient outcomes and quality of life when oral iron therapy is inadequate.